Accordingly, IGF2BP1 depletion enhanced T cell activation and tumor cell killing in the presence of HLA-matched PBMCs, as evidenced by increased IFNγ secretion (Fig. 2d), elevated granzyme B (GZMB) levels within tumor cells (Fig. 2e), and enhanced caspase-3/7 activity (Fig. 2f and Supplementary Fig. S2b for an alternative siRNA). This evidence concerns the gene IGF2BP1 and neoplasm.